Dynavax and Mount Sinai announced collaboration to develop a universal influenza vaccine candidate with CpG 1018 adjuvant
On Jul. 16, 2020, Dynavax Technologies and the Icahn School of Medicine at Mount Sinai announced they had…
NIH launched clinical trials network to test COVID-19 vaccines and other prevention tools
On Jul. 8, 2020, the National Institute of Allergy and Infectious Diseases announced it had established a new…
Eli Lilly began world’s first study of a potential COVID-19 antibody treatment in humans
On Jun. 1, 2020, Eli Lilly announced patients had been dosed in the world’s first study of a…
Emory University launched study on COVID-19 immune responses
On Apr. 30, 2020, Emory University researchers are taking part in a multi-site study across the U.S. to…
NIAID strategic plan detailed COVID-19 research priorities
On Apr. 23, 2020, a new strategic plan from the National Institute of Allergy and Infectious Diseases (NIAID),…
RedHill Biopharma announced agreement with NIAID to evaluate RHB-107 against COVID-19
On Apr. 20, 2020, RedHill Biopharma announced an agreement with the National Institute of Allergy and Infectious Diseases…
BioCryst began clinical trial with Galidesivir for treatment of patients with COVID-19
On Apr. 9, 2020, BioCryst Pharmaceuticals announced the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical…
OncoSec collaborated with Providence Cancer Institute to conduct first-in-human trial of CORVax12, an Investigational Vaccine to prevent COVID-19
On Apr. 6, 2020, OncoSec Medical announced that Providence Cancer Institute, a part of Providence St. Joseph Health…
Aimmune announced first U.S. patients treated with PALFORZIA, the first treatment for peanut allergy
On Mar. 16, 2020, Aimmune Therapeutics announced that the first patients in the U.S. were being treated with…
OHSU, partners Kineta, U of Washington, VGTI Florida awarded $10 million NIH contract to develop new vaccine adjuvants
On Oct. 20, 2014, Oregon Health & Science University’s Vaccine & Gene Therapy Institute (OHSU) announced it was…
ACIP voted to recommend FluBlok influenza vaccine for people age 18 through 49ﾠ with egg allergy
On Jun. 20, 2013, the Advisory Committee on Immunization Practices (ACIP) voted 13 to 0, in favor of…
Jubilant Organosys acquired Hollister-Stier
On Apr. 25, 2007, Jubilant Organosys, Ltd. announced it had acquired Spokane-based Hollister-Stier for $122.5 million. The plant…
Agriculture | Biology | Diagnostics | FDA | Therapeutics | U.S. Congress
Passage of Food Allergy Labeling Act required labeling of foods that may cause allergic reaction
On Dec. 12, 2005, the U.S. Congress approved the passage of the Food Allergy Labeling and Consumer Protection…
OHSU was awarded $4 million NIH biodefense contract to study tuberculosis
On Nov. 1, 2004, an Oregon Health & Science University (OHSU) research team announced that it was one…
Biotechnology | NIH | Vaccine
NIAID awarded a new license agreement for RotaShield, an oral rotavirus vaccine
On May 4, 2004, the National Institute of Allergy and Infectious Diseases (NIAID), awarded a new license agreement…
Hollister-Stier became Bayer Pharmaceuticals
In 1995, Hollister-Stier became Bayer Pharmaceuticals. Bayer had acquired Cutter in 1974 and Miles in 1978. Hollister-Stier Laboratories,…
The Food Allergy & Anaphylaxis Network was established
In 1991, FAAN (The Food Allergy & Anaphylaxis Network) was established by Anne Munoz-Furlong, at a time when…
Hollister-Stier Laboratories became a division of the Miles Pharmaceutical Group
In 1983, Hollister-Stier Laboratories became a division of the Miles Pharmaceutical Group. Hollister-Stier Laboratories, located in Spokane, was…
Kimishige Ishizaka, along with his wife Teruko Ishizaka, first described a new antibody isotype: immunoglobulin E (IgE)
In 1966, Kimishige (“Kimi”) Ishizaka, along with his wife Teruko (‘Terry’) Ishizaka, first described a new antibody isotype:…
Hollister-Stier Laboratories became a subsidiary of Cutter Laboratories
In 1958, Hollister-Stier Laboratories became a subsidiary of Cutter Laboratories. Hollister-Stier Laboratories, located in Spokane, was founded by…
Dr. James Bowman studied favism, the deficiency of glucose-6-dehydrogenase
In 1955, geneticist Dr. James Bowman studied favism, the deficiency of glucose-6-dehydrogenase, in Iran. Favism is an acute…
Chester Emmons first pointed out reservoirs of cryptococcosi in soil and pigeon droppings
In 1951, Chester Emmons from the National Institute of Allergy and Infectious Diseases first pointed out reservoirs of…
Chester Emmons first pointed out reservoirs of histoplasmosis in soil and bats
In 1948, Chester Emmons from the National Institute of Allergy and Infectious Diseases first pointed out reservoirs of…
Chester Emmons first pointed out reservoirs of coccidiomycosis in soil
In 1942, Chester Emmons from the National Institute of Allergy and Infectious Diseases first pointed out reservoirs of…
Hollister-Stier Laboratories was founded in Spokane by chemist Guy Hollister and Robert E Stier, MD
In 1921, Hollister-Stier Laboratories, located in Spokane, is the oldest name in allergy science. The company was founded…
The word “allergen” first used in reference to allergic antibodies
In 1910, John F. Anderson and Wade H. Frost extended earlier studies on hypersensitivity and used for the…
The first description of allergies was published
On Mar. 16, 1844, John Bostock, Jr., an English physician, published the first description of allergies in Medico-Chirurgical…